Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory
- PMID: 25577033
- DOI: 10.1007/s10928-014-9402-0
Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory
Abstract
Domain antibodies (dAbs) are the smallest antigen-binding fragments of immunoglobulins. To date, there is limited insight into the pharmacokinetics of dAbs, especially their distribution into tissues and elimination. The objective of this work was to develop a physiologically-based pharmacokinetic model to investigate the biodisposition of a non-specific dAb construct in mice. Following a single IV administration of 10 mg/kg dummy dAb protein to twenty four female mice, frequent blood samples were collected and whole body lateral sections were analyzed by quantitative whole-body autoradiography. The model is based on the two-pore hypothesis of extravasation where organ-specific isogravimetric flow rates (Jorg,ISO) and permeability-surface area products (PSorg) are expressed as linear functions of the lymph flow rate (Jorg) and the kidney compartment is modified to account for glomerular filtration of dAb. As a result, only Jorg, glomerular filtration coefficient and the combined volume of Bowman's capsule, proximal and distal renal tubules and loop of Henle were optimized by fitting simultaneously all blood and organ data to the model. Our model captures the pharmacokinetic profiles of dAb in blood and all organs and shows that extravasation into interstitial space is a predominantly diffusion-driven process. The parameter values were estimated with good precision (%RMSE ≈ 30) and low cross-correlation (R(2) < 0.2). We developed a flexible model with a limited parameter number that may be applied to other biotherapeutics after adapting for size-related effects on extravasation and renal elimination processes.
Similar articles
-
Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice.Cancer Res. 1994 Mar 15;54(6):1517-28. Cancer Res. 1994. PMID: 8137258
-
Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats.J Pharmacokinet Pharmacodyn. 2019 Aug;46(4):339-359. doi: 10.1007/s10928-019-09640-9. Epub 2019 May 11. J Pharmacokinet Pharmacodyn. 2019. PMID: 31079322
-
Renal aluminium handling in the rat: a micropuncture assessment.Clin Sci (Lond). 2004 Aug;107(2):159-65. doi: 10.1042/CS20040052. Clin Sci (Lond). 2004. PMID: 15053741
-
Renal control of sodium homeostasis.Ann Clin Lab Sci. 1981 Jul-Aug;11(4):322-6. Ann Clin Lab Sci. 1981. PMID: 7023345 Review. No abstract available.
-
Sodium handling by the kidney in health and disease. A review.S Afr Med J. 1973 May 19;47(19):839-43. S Afr Med J. 1973. PMID: 4575117 Review. No abstract available.
Cited by
-
Mathematical Models to Characterize the Absorption, Distribution, Metabolism, and Excretion of Protein Therapeutics.Drug Metab Dispos. 2022 Jun;50(6):867-878. doi: 10.1124/dmd.121.000460. Epub 2022 Feb 23. Drug Metab Dispos. 2022. PMID: 35197311 Free PMC article. Review.
-
Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.J Pharmacokinet Pharmacodyn. 2020 Oct;47(5):385-409. doi: 10.1007/s10928-020-09691-3. Epub 2020 Jun 4. J Pharmacokinet Pharmacodyn. 2020. PMID: 32500362 Free PMC article.
-
Physiologically Based Pharmacokinetic Modeling to Characterize the Effect of Molecular Charge on Whole-Body Disposition of Monoclonal Antibodies.AAPS J. 2023 Apr 28;25(3):48. doi: 10.1208/s12248-023-00812-7. AAPS J. 2023. PMID: 37118220
-
Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins.J Pharmacokinet Pharmacodyn. 2024 Oct;51(5):449-476. doi: 10.1007/s10928-024-09922-x. Epub 2024 May 1. J Pharmacokinet Pharmacodyn. 2024. PMID: 38691205
-
A new pharmacokinetic model for 90Y-ibritumomab tiuxetan based on 3-dimensional dosimetry.Sci Rep. 2018 Oct 5;8(1):14860. doi: 10.1038/s41598-018-33160-0. Sci Rep. 2018. PMID: 30291297 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials